National Institutes of Health to Grant Exclusive Patent License to Kite Pharma for Cancer Treatment

Summary

The National Institutes of Health is issuing a notice of intent to grant an exclusive patent license to Kite Pharma, Inc. for the development of T cell receptors for adoptive transfer in humans to treat cancer, as outlined in patent applications filed by the NIH.